Einat Metzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Einat metzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Einat Metzer Today - Breaking & Trending Today
Einat Metzer is CEO and co-founder of Emedgene, a leading precision medicine intelligence company. Which disease results in the highest total economic burden per annum? If you guessed diabetes, cancer, heart disease or even obesity, you guessed wrong. Reaching a mammoth financial burden of $966 billion in 2019, the cost of rare diseases far outpaced diabetes ($327 billion), cancer ($174 billion), heart disease ($214 billion) and other chronic diseases. Cognitive intelligence, or cognitive computing solutions, blend artificial intelligence technologies like neural networks, machine learning, and natural language processing, and are able to mimic human intelligence. It’s not surprising that rare diseases didn’t come to mind. By definition, a rare disease affects fewer than 200,000 people. However, collectively, there are thousands of rare diseases and those affect around 400 million people worldwide. About half of rare disease patients are children, and th ....
Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership Illumina has launched a nonexclusive partnership with Emedgene, an artificial intelligence-based precision medicine company, to integrate automated interpretation of rare genetic disease data into Illumina’s TruSight™ Software Suite. Through the collaboration, whose value has not been disclosed, TruSight will include Emedgene’s clinical rare disease application, one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases. Illumina and Emedgene reason that through AI-enhanced interrogation of medical literature and phenotypes associated with rare disease, researchers will be better able to make new and unexpected discoveries based on rare disease data. ....
Emedgene collaborates with Illumina to scale the interpretation of genomic data for rare diseases USA - English News provided by Share this article Share this article PALO ALTO, California, Dec. 16, 2020 /PRNewswire/ Emedgene, a leading precision medicine intelligence company, announces a non-exclusive partnership with Illumina Inc. and the integration of automated interpretation into Illumina s TruSight™ Software Suite for rare genetic diseases. Emedgene s Clinical Rare Disease application is one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases. Healthcare is in the midst of a leap towards precision medicine. Continued improvements in the cost of next-generation sequencing (NGS) technologies, such as those developed by Illumina, have dramatically accelerated the adoption of genetic testing. Consequently, data generated from genomics doubles every ....